CBCT for MRONJ: How 3D Imaging Supports Early Detection and Staging of Medication-Related Osteonecrosis of the Jaw

CBCT MRONJ imaging is transforming how clinicians detect and stage medication-related osteonecrosis of the jaw. Prescriptions of bisphosphonates and denosumab continue to rise. As a result, dentists and oral surgeons increasingly encounter patients at risk. Three-dimensional cone beam CT provides the spatial resolution needed to spot early bone changes. These changes are ones that two-dimensional radiography consistently misses.

This article explains when CBCT MRONJ assessment is indicated and what findings to expect at each stage. It draws on current SDCEP guidance and peer-reviewed evidence to help referring clinicians make informed imaging decisions.

Quick Answer: Why Request a CBCT for MRONJ Assessment?

Conventional radiographs detect MRONJ only after substantial bone destruction has occurred. In contrast, CBCT identifies early-stage changes. These include focal osteosclerosis, lamina dura thickening, and widening of the periodontal ligament space. Such findings allow clinicians to intervene before the disease progresses to bone exposure or pathological fracture. Furthermore, CBCT provides the three-dimensional detail needed for surgical planning.

What Is MRONJ and Why Does It Matter for Referring Clinicians?

Medication-related osteonecrosis of the jaw is a condition where bone in the maxilla or mandible becomes necrotic. It occurs in patients taking antiresorptive or antiangiogenic drugs. The most commonly implicated medications include oral and intravenous bisphosphonates. Examples are alendronic acid and zoledronic acid. The monoclonal antibody denosumab is also implicated. Clinicians prescribe these drugs widely for osteoporosis, bone metastases, and Paget’s disease.

MRONJ typically presents as exposed bone that fails to heal within eight weeks. It often follows a dental extraction or other dentoalveolar surgery. However, early-stage disease can exist without clinical bone exposure. This makes radiological detection essential. The Scottish Dental Clinical Effectiveness Programme (SDCEP) provides UK-specific guidance on managing patients at risk of MRONJ. The guidance covers risk stratification and pre-extraction imaging protocols.

For implantologists, MRONJ risk assessment is particularly important. Placing implants in patients on long-term antiresorptive therapy carries a heightened risk. A thorough pre-operative CBCT assessment helps identify subclinical bone changes. These changes would contraindicate immediate implant placement.

CBCT MRONJ Staging: What Each Disease Stage Looks Like on 3D Imaging

The American Association of Oral and Maxillofacial Surgeons (AAOMS) staging system classifies MRONJ from Stage 0 to Stage 3. CBCT adds significant diagnostic value at every stage. It is especially useful in the early phases where clinical examination alone falls short.

Stage 0: At-Risk or Subclinical Disease

Patients at this stage have no clinical bone exposure. They may show non-specific symptoms such as jaw pain, dull aching, or tooth loosening. On CBCT, early findings include focal osteosclerosis and lamina dura thickening. Increased prominence of the inferior alveolar canal wall is also visible. These subtle changes are invisible on panoramic radiographs. Consequently, CBCT MRONJ screening at this stage allows early intervention.

Stage 1: Exposed Bone Without Infection

At this stage, exposed necrotic bone is present clinically. There is no evidence of infection. CBCT typically reveals a localised area of dense, sclerotic bone. Loss of normal trabecular architecture is apparent. The three-dimensional view helps clinicians determine the full extent of the affected area. This area frequently extends beyond what is visible on clinical examination.

Stage 2: Exposed Bone With Infection

In addition to bone exposure, patients at Stage 2 present with pain, erythema, and purulent discharge. CBCT imaging shows irregular bone destruction and periosteal reaction. Sequestration is sometimes visible. Importantly, CBCT delineates the boundaries of necrotic bone relative to vital structures. These include the inferior alveolar nerve and the maxillary sinus floor. This information is critical for planning surgical debridement.

Stage 3: Advanced Disease

Stage 3 involves extensive necrosis extending beyond the alveolar bone. It can cause pathological fracture, extraoral fistula, or oroantral communication. CBCT is essential for mapping the full extent of bone loss. It also identifies cortical perforation and helps plan resection margins. Similarly, it helps surgeons assess whether reconstruction with a free flap or plate will be needed.

When to Request CBCT MRONJ Imaging: Clinical Indications

Not every patient on antiresorptive medication requires a CBCT scan. However, several clinical scenarios strongly justify advanced imaging.

Patients on bisphosphonates for more than three years who need dentoalveolar surgery represent a key group. The SDCEP guidance identifies cumulative exposure as a significant risk factor. Pre-operative CBCT helps identify subclinical disease that would alter the surgical approach. In particular, patients on intravenous bisphosphonates for oncological indications carry the highest risk.

Unexplained jaw pain or tooth mobility in patients taking antiresorptive drugs is another clear indication. When clinical examination reveals no obvious dental cause, CBCT can detect the early osteosclerotic changes characteristic of Stage 0 MRONJ. Additionally, patients with non-healing extraction sockets should be imaged promptly. Delayed healing beyond eight weeks is a diagnostic criterion for MRONJ.

Pre-implant assessment in patients with a history of antiresorptive therapy also warrants CBCT. As noted in 3Beam’s guide to CBCT for pre-implant planning, volumetric imaging reveals bone quality and quantity at the proposed site. For patients at MRONJ risk, this assessment takes on added importance. Areas of subclinical osteosclerosis may indicate compromised healing potential.

What CBCT Reveals That OPG and Periapical Radiographs Cannot

Two-dimensional radiographs have well-documented limitations in detecting MRONJ. Panoramic radiographs (OPGs) provide a broad overview. However, they lack the resolution to identify early trabecular changes. Periapical radiographs offer better detail in a small field. They cannot show the three-dimensional extent of disease.

A 2025 narrative review published in Medicina confirmed that CBCT and MRI were the most sensitive modalities for early MRONJ detection. Specifically, CBCT identified osteosclerosis and cortical thickening in patients with normal-appearing OPGs. The study also highlighted that CBCT accurately delineated sequestra and periosteal new bone formation. These findings directly influence surgical planning.

For further reading on how CBCT detects bone loss around failing dental implants, see our dedicated guide on peri-implantitis imaging.

The Role of Bone Density Scanning in MRONJ Risk Assessment

MRONJ is most commonly a consequence of antiresorptive therapy prescribed for osteoporosis. Therefore, understanding a patient’s bone density status provides valuable clinical context. Patients with confirmed osteoporosis are more likely to be on long-term bisphosphonate or denosumab therapy. This directly increases their MRONJ risk.

DEXA London, 3Beam’s sister service, offers bone density scanning at the same 86 Harley Street address. A DEXA scan quantifies bone mineral density and calculates the FRAX fracture risk score. This helps clinicians understand why a patient is on antiresorptive medication. It also indicates how long they are likely to continue treatment. This information directly informs the MRONJ risk stratification process in the SDCEP guidance.

SDCEP Risk Stratification and Imaging Protocol

The SDCEP 2024 guidance stratifies MRONJ risk based on three factors: the type of antiresorptive drug, duration of use, and additional risk factors. Additional risk factors include concurrent corticosteroid therapy and diabetes. Patients on oral bisphosphonates for fewer than three years with no additional risk factors are classified as low risk. Those on intravenous bisphosphonates or oral bisphosphonates for more than five years carry a higher risk.

For higher-risk patients requiring dentoalveolar surgery, SDCEP recommends careful pre-operative assessment. The guidance does not mandate CBCT for all at-risk patients. However, the evidence base strongly supports its use when clinical findings are equivocal. Notably, CBCT enables the clinician to assess residual bone volume. It also identifies the extent of any existing necrosis and supports planning the least traumatic surgical approach.

How 3Beam’s CBCT MRONJ Reporting Supports Surgical Teams

At 3Beam Imaging Centre, every CBCT scan can include a formal report from a UK Dental Radiologist. The referring clinician simply requests this at the time of booking. For suspected MRONJ cases, the report addresses osteosclerosis, cortical integrity, sequestration, periosteal reaction, and proximity to vital structures.

This structured approach follows the principles outlined in our guide to structured dental CBCT radiology reports. The report gives the surgical team a written clinical interpretation before any intervention. This reduces diagnostic uncertainty and supports informed consent discussions.

Same-day and next-day appointments are available. This is particularly important for MRONJ cases where timely diagnosis influences treatment outcomes. The Planmeca and Morita CBCT scanners at 3Beam provide high-resolution, low-dose imaging. They deliver the detailed assessment of cortical and trabecular bone architecture that MRONJ evaluation demands.

Frequently Asked Questions

Q: Can an OPG reliably detect MRONJ?
A: An OPG can show late-stage bone destruction but frequently misses early MRONJ. Published evidence confirms that CBCT detects osteosclerotic changes and lamina dura thickening invisible on panoramic radiographs. For this reason, CBCT is the preferred modality when MRONJ is suspected.

Q: Should I request a CBCT before extracting a tooth in a patient on bisphosphonates?
A: It depends on the patient’s risk profile. For those on oral bisphosphonates for fewer than three years with no additional risk factors, a CBCT may not be necessary. However, for patients with longer exposure or intravenous bisphosphonate use, pre-extraction CBCT is strongly recommended.

Q: How does CBCT help plan surgical treatment for established MRONJ?
A: CBCT provides precise three-dimensional mapping of necrotic bone, sequestra, and periosteal reactions. This allows the surgeon to plan debridement margins accurately and avoid vital structures. It also helps determine whether conservative or radical intervention is appropriate.

Q: Is CBCT MRONJ imaging safe for patients already receiving treatment for cancer?
A: Yes. CBCT delivers a substantially lower radiation dose than medical CT. The effective dose from a dental CBCT scan is typically 20 to 200 microsieverts. That is comparable to a few days of natural background radiation. The diagnostic benefit far outweighs the minimal additional dose.

Q: Can CBCT differentiate MRONJ from other jaw pathologies?
A: CBCT helps distinguish MRONJ from osteomyelitis, osteoradionecrosis, and metastatic bone disease. It identifies the characteristic pattern of osteosclerosis and sequestration in the context of antiresorptive drug use. However, biopsy may still be required in ambiguous cases.

The Bottom Line on CBCT MRONJ Assessment

CBCT MRONJ imaging provides the three-dimensional detail that two-dimensional radiography cannot match. It detects early subclinical changes, accurately stages established disease, and provides the anatomical information needed for safe treatment planning. As antiresorptive prescribing continues to grow, the ability to identify and stage MRONJ promptly will become essential for every dental and surgical team.

For referring clinicians managing patients on bisphosphonates or denosumab, a timely CBCT assessment can make the difference between early conservative management and late-stage surgical intervention. The evidence supports proactive imaging in at-risk patients, particularly before dentoalveolar surgery.